AbbVie Acquires Mitokinin
October 5, 2023
AbbVie has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a selective PINK1 activator for Parkinson's disease. AbbVie paid $110 million at closing with up to $545 million in additional milestone payments plus tiered royalties contingent on development and commercial milestones.
- Buyers
- AbbVie
- Targets
- Mitokinin
- Sellers
- Mitokinin shareholders
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.